Novo Nordisk

Novo Nordisk

Global healthcare company with 95 years of innovation and leadership in diabetes care. Learn more

Launch date
Employees
Market cap
CAD818.8b
Enterprise valuation
CAD817.6b (Public information from Sep 2024)
Company register number 24256790
Gladsaxe Municipality Capital Region of Denmark (HQ)
Corporate Venture Fund: Novo Ventures, Novo Holdings

Financials

Estimates*

Edit
Revenues, earnings & profits over time
DKK2020202120222023202420252026
Revenues126.9b140.8b177.0b232.3b290.1b349.3b406.4b
% growth4 %11 %26 %31 %25 %20 %16 %
EBITDA60.2b67.6b82.0b112.9b142.3b176.6b208.2b
% EBITDA margin47 %48 %46 %49 %49 %51 %51 %
Profit42.1b47.8b55.5b83.7b102.0b128.0b149.4b
% profit margin33 %34 %31 %36 %35 %37 %37 %
EV / revenue7.8x12.0x12.0x13.4x14.4x11.9x10.1x
EV / EBITDA16.3x24.9x25.9x27.5x29.3x23.5x19.7x
R&D budget15.5b17.8b24.0b32.4b---
R&D % of revenue12 %13 %14 %14 %---

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
-

N/A

-
N/A

N/A

IPO
N/A

$22.0m

Post IPO Equity

$55.9m

Post IPO Equity
*

$294k

Post IPO Equity
*
N/A

N/A

Post IPO Equity
Total Funding-

Recent News about Novo Nordisk

Edit
More about Novo Nordiskinfo icon
Edit

Novo Nordisk, founded in 1923 and headquartered in Denmark, is a leading global healthcare company specializing in diabetes care, obesity treatment, and chronic disease management. The company develops and manufactures innovative medicines that are approved for specific indications in various countries and regions. Novo Nordisk serves a diverse range of clients, including healthcare providers, patients, and governments, operating primarily in the pharmaceutical and biotechnology markets. The business model focuses on research and development, production, and distribution of life-saving medicines, generating revenue through the sale of these pharmaceutical products. The company is committed to sustainability, aiming to reduce its environmental impact while expanding access to essential medicines for vulnerable populations. Novo Nordisk is also dedicated to building strong relationships with suppliers and continuously seeks talented individuals to join their team.

Keywords: diabetes care, obesity treatment, chronic disease, innovative medicines, healthcare, biotechnology, sustainability, pharmaceutical, research and development, global market.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit

Investments by Novo Nordisk

Edit
FORMA Therapeutics
ACQUISITION by Novo Nordisk Sep 2022
PIERIS Proteolab
ACQUISITION by Palvella Therapeutics Jul 2024
Xellia Pharmaceuticals
ACQUISITION by Novo Nordisk May 2013
EMISPHERE TECHNOLOGIES
ACQUISITION by Novo Nordisk Nov 2020
Dicerna Pharmaceuticals
ACQUISITION by Novo Nordisk Nov 2021
Novozymes
exited
View 281 more